fibrinolytic drugs

fibrinolytic drugs

agents used in the immediate treatment of acute myocardial infarction, but also in deep-vein thrombosis, pulmonary embolism and diabetes-related retinal embolism management; side-effects include prolonged bleeding; e.g. streptokinase
References in periodicals archive ?
1 Market Shares (%) of Leading Fibrinolytic Drugs, 2010
Both these fibrinolytic drugs act on plasminogen, by cleavage to plasmin.
The statement outlines multiple treatment options including the use of fibrinolytic drugs (drugs that dissolve blood clots), catheter-based interventions (inserting a small plastic catheter into an artery to open it), treatment with surgery to remove the blood clots and use of implants called filters that prevent clots from traveling in the veins from the legs to the lungs, where they can cause strain on the heart.
The trial, known as Early RETAVASE-Thrombolysis In Myocardial Infarction (ER-TIMI) 19, was conducted in states where pre-hospital administration of fibrinolytic drugs such as RETAVASE currently is authorized*.